Advertisement

Methodologies of Safety Assessment in Clinical Pharmacology

  • Werner SeizEmail author
Living reference work entry

Abstract

An important objective of clinical pharmacology is the early and ongoing assessment of the safety and tolerability of a new drug. This is done by assessing the type, frequency, and severity of side effects, assessing in which patient population these side effects may occur at which dose or exposure, for what duration and whether these side effects can be monitored and whether they are reversible. The terminology for the safety assessment of drugs has some specifics that need to be explained right at the beginning of this chapter.

References and Further Reading

  1. Cancer Therapy Evaluation Program (2009) Common terminology criteria for adverse events (CTCAE) v4.0. Accessed 29 May 2009Google Scholar
  2. Brentano CF, Menard J (2016) The BIAL/Bootrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: are we missing the fundamentals. Presse Med 9:719–722CrossRefGoogle Scholar
  3. EMA (2017) Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. EMEA/CHMP/SWO/28367/07 Rev. 1Google Scholar
  4. FDA Draft Guidance (2007) Guidance on industry drug induced liver injury: premarketing clinical evaluation. CDER, Rockville, MD, USAGoogle Scholar
  5. FDA Guidance (2007) Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, Rockville, MD, USAGoogle Scholar
  6. FDA Guidance (2009) Drug-induced liver injury: premarketing clinical evaluation, Rockville, MD, USAGoogle Scholar
  7. Herson J (2000) Data and safety monitoring committees in clinical trials. Chapman & Hall, Boca Raton, p 48Google Scholar
  8. Horvath CJ, Milton MN (2009) The TeGenero incident and the Duff report conclusions: a series of unfortunate events or an avoidable event? Toxicol Pathol 37(3):372–383CrossRefGoogle Scholar
  9. ICH (2005) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of non-antiarrhythmic drugs. ICH harmonized tripartite guideline E14, final versionGoogle Scholar
  10. Kratz A, Ferraro M, Sluss P, Lewandroski K (2004) Laboratory reference values. N Engl J Med 351:1548–1563CrossRefGoogle Scholar
  11. Lewis JH (2006) “Hy’s law”, the “Rezulin rule”, and other predictors of severe drug-induced hepatotoxicity: putting risk benefit into perspective. Pharmacoepidemiol Drug Saf 15:221–229CrossRefGoogle Scholar
  12. Lock EA (2010) Sensitive and early markers of renal injury: where are we and what is the way forward. Toxicol Sci 116:1–4CrossRefGoogle Scholar
  13. Sibille M, Patat A, Caplain H, Donazzolo (2010) A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies. Br J Clin Pharmacol.  https://doi.org/10.1111/1365-2125.2010.03741.x

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.R&D Translational Medicine and Clinical PharmacologySanofi-Aventis Deutschland GmbHFrankfurt am MainGermany

Personalised recommendations